Abstract
Bone marrow organoids (BMOs) derived from human induced pluripotent stem cells (hiPSCs) replicate key hematopoietic and stromal cell populations of the human bone marrow niche, providing a platform for disease modelling of hematological diseases. However, the 14–19-day differentiation process required for BMO generation limits their on-demand availability. We considered that cryopreservation of BMOs could address this bottleneck, and we therefore assessed controlled-rate cryopreservation of fully differentiated BMOs generated from four hiPSC lines (11599, BU3, Bioni10-C, and Bioni37-A) using a DMSO-based cryopreservation medium. Post-thaw viability, cellular composition, and organoid architecture were evaluated by flow cytometry and histological assessment after six days of recovery culture. Post-thaw viability was variable across the hiPSC lines and differentiation batches and did not consistently correlate with pre-cryopreservation viability, suggesting that biological factors intrinsic to individual differentiation runs are important determinants of cryopreservation outcome. BMOs derived from the 11599 hiPSC line showed the most consistent recovery, with post-thaw viability, cellular composition and organoid morphology comparable to pre-freeze conditions across three independent batches. These findings suggest that controlled-rate cryopreservation of fully differentiated BMOs is feasible and identify hiPSC line identity and differentiation batch quality as potential determinants of post-thaw recovery, supporting further development of BMO biobanking strategies.